ArticleEndoscopy international open2026
Octreotide for prevention of delayed bleeding after endoscopic mucosal resection for large superficial non-ampullary duodenal tumors.
Article in Endoscopy international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and study aims: Effective strategies to prevent delayed bleeding (DB) following endoscopic mucosal resection (EMR) for large superficial non-ampullary duodenal tumors (SNADTs) remain limited. Octreotide exerts pharmacological effects that may influence hemostasis and thereby reduce bleeding risk. This exploratory study aimed to evaluate the association between postprocedural octreotide use and DB after duodenal EMR for large SNADTs. Patients and methods: This single-center, exploratory, retrospective study included all hot EMRs for large SNADTs ≥ 10 mm (2015-2024). Routine post-procedural intravenous octreotide (50 μg/h) was introduced in 2022, administered immediately post-EMR at 50 μg/hour during overnight observation. DB was defined as clinically significant bleeding within 30 days requiring prolonged hospitalization, readmission, or intervention. Results: A total of 107 SNADTs (median diameter 25 mm; interquartile range 15-40) were resected, including 33 treated with octreotide. Overall, DB occurred in 20% of patients (21/107), including 24% (18/74) in the control group and 9% (3/33) in the octreotide group. In logistic regression adjusting for lesion size and propensity score, octreotide showed a non-significant trend toward reduced DB overall (odds ratio [OR] 0.34; 95% confidence interval [CI] 0.08-1.17; Conclusions: In this exploratory study, postprocedural intravenous octreotide appeared to be associated with a lower occurrence of DB after EMR for large SNADTs (≥ 30 mm). Larger, prospective studies are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.